These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 34668834

  • 1. Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A.
    Soliman M, Osman N, Hefnawy S, El Hawy MA.
    Pediatr Hematol Oncol; 2022 May; 39(4):318-328. PubMed ID: 34668834
    [Abstract] [Full Text] [Related]

  • 2. [Relationship between plasma levels of thrombin activatable fibrinolysis inhibitor, plasminogen activator inhibitor-1 and tissue-type plasminogen activator and deep venous thrombosis in patients with systemic lupus erythematosus].
    Liu YF, Hou N, Shi YJ, Li CX, Gao YJ, Liu LN.
    Zhonghua Yi Xue Za Zhi; 2023 Jun 06; 103(21):1638-1642. PubMed ID: 37248064
    [Abstract] [Full Text] [Related]

  • 3. Thrombin activatable fibrinolysis inhibitor pathway alterations correlate with bleeding phenotype in patients with severe hemophilia A.
    Semeraro F, Mancuso ME, Ammollo CT, Dirienzo L, Vitulli A, Santagostino E, Tripodi A, Colucci M.
    J Thromb Haemost; 2020 Feb 06; 18(2):381-389. PubMed ID: 31571361
    [Abstract] [Full Text] [Related]

  • 4. Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and TAFI in advanced carotid plaque.
    Jönsson Rylander AC, Lindgren A, Deinum J, Bergström GM, Böttcher G, Kalies I, Wåhlander K.
    J Thromb Haemost; 2017 Apr 06; 15(4):758-769. PubMed ID: 28135035
    [Abstract] [Full Text] [Related]

  • 5. The hyperfibrinolytic state of mice with combined thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 gene deficiency is critically dependent on TAFI deficiency.
    Vercauteren E, Peeters M, Hoylaerts MF, Lijnen HR, Meijers JC, Declerck PJ, Gils A.
    J Thromb Haemost; 2012 Dec 06; 10(12):2555-62. PubMed ID: 23083123
    [Abstract] [Full Text] [Related]

  • 6. Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
    Antovic JP, Schulman S, An SS, Greenfield RS, Blombäck M.
    Scand J Clin Lab Invest; 2004 Dec 06; 64(8):745-51. PubMed ID: 15719893
    [Abstract] [Full Text] [Related]

  • 7. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
    Akinci B, Comlekci A, Yener S, Demir T, Ozcan MA, Bayraktar F, Yesil S.
    Endocr J; 2007 Aug 06; 54(4):593-9. PubMed ID: 17690487
    [Abstract] [Full Text] [Related]

  • 8. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N, Guldiken S, Demir M, Tugrul A.
    Clin Appl Thromb Hemost; 2010 Oct 06; 16(5):568-73. PubMed ID: 19959491
    [Abstract] [Full Text] [Related]

  • 9. Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding.
    Wyseure T, Cooke EJ, Declerck PJ, Behrendt N, Meijers JCM, von Drygalski A, Mosnier LO.
    Blood; 2018 Oct 11; 132(15):1593-1603. PubMed ID: 30026184
    [Abstract] [Full Text] [Related]

  • 10. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
    Erem C, Nuhoglu I, Yilmaz M, Kocak M, Demirel A, Ucuncu O, Onder Ersoz H.
    J Endocrinol Invest; 2009 Feb 11; 32(2):169-74. PubMed ID: 19411818
    [Abstract] [Full Text] [Related]

  • 11. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
    Yener S, Akarsu M, Demir T, Akinci B, Sagol O, Bayraktar F, Ozcan MA, Tankurt E, Yesil S.
    J Endocrinol Invest; 2007 Nov 11; 30(10):810-9. PubMed ID: 18075282
    [Abstract] [Full Text] [Related]

  • 12. Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway.
    Colucci M, Incampo F, Cannavò A, Menegatti M, Siboni SM, Zaccaria F, Semeraro N, Peyvandi F.
    J Thromb Haemost; 2016 Aug 11; 14(8):1603-14. PubMed ID: 27094709
    [Abstract] [Full Text] [Related]

  • 13. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
    Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O.
    Eur J Endocrinol; 2009 May 11; 160(5):863-8. PubMed ID: 19233920
    [Abstract] [Full Text] [Related]

  • 14. Elucidating the molecular mechanisms of fibrinolytic shutdown after severe injury: The role of thrombin-activatable fibrinolysis inhibitor.
    Coleman JR, Moore EE, Kelher MR, Jones K, Cohen MJ, Banerjee A, Silliman CC.
    J Trauma Acute Care Surg; 2023 Jun 01; 94(6):857-862. PubMed ID: 36787438
    [Abstract] [Full Text] [Related]

  • 15. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
    Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S, Doggen CJ, Rosendaal FR.
    Blood; 2010 Jul 08; 116(1):113-21. PubMed ID: 20385790
    [Abstract] [Full Text] [Related]

  • 16. Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients.
    Fernandez-Cadenas I, Alvarez-Sabin J, Ribo M, Rubiera M, Mendioroz M, Molina CA, Rosell A, Montaner J.
    J Thromb Haemost; 2007 Sep 08; 5(9):1862-8. PubMed ID: 17723126
    [Abstract] [Full Text] [Related]

  • 17. Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 by a heterodimer diabody.
    Develter J, Booth NA, Declerck PJ, Gils A.
    J Thromb Haemost; 2008 Nov 08; 6(11):1884-91. PubMed ID: 18752580
    [Abstract] [Full Text] [Related]

  • 18. TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding.
    Wyseure T, Yang T, Zhou JY, Cooke EJ, Wanko B, Olmer M, Agashe R, Morodomi Y, Behrendt N, Lotz M, Morser J, von Drygalski A, Mosnier LO.
    JCI Insight; 2019 Oct 03; 4(19):. PubMed ID: 31465300
    [Abstract] [Full Text] [Related]

  • 19. Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A.
    Foley JH, Nesheim ME, Rivard GE, Brummel-Ziedins KE.
    Haemophilia; 2012 May 03; 18(3):e316-22. PubMed ID: 21933309
    [Abstract] [Full Text] [Related]

  • 20. Association of TAFI gene polymorphisms with severity of coronary stenosis in stable coronary artery disease.
    Rattanawan C, Komanasin N, Settasatian N, Settasatian C, Kukongviriyapan U, Intharapetch P, Senthong V.
    Thromb Res; 2018 Nov 03; 171():171-176. PubMed ID: 30321704
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.